Noticias de AKTS_US

Noticias del mercado

Últimas noticias sobre AKTS_US — 122 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: AKTS_US ✕ 122 resultados
06/05/2026 AKTS_US — ChartMill
Aktis Oncology to Present at the BofA Securities Health Care Conference
05/05/2026 AKTS_US — TradingView
AKTS: AKY-2519 advances in Phase I-B trials for mCRPC and B7H3-expressing tumors, with key data ahead
04/05/2026 AKTS_US — Investing.com South Africa
Aktis initiates phase 1b trial of AKY-2519 in prostate cancer By Investing.com
04/05/2026 AKTS_US — Investing.com Australia
Aktis initiates phase 1b trial of AKY-2519 in prostate cancer
04/05/2026 AKTS_US — Investing.com UK
Aktis initiates phase 1b trial of AKY-2519 in prostate cancer
04/05/2026 AKTS_US — GlobeNewswire
Aktis Oncology Initiates Phase 1b Clinical Trial for

La estrategia de desarrollo clínico incluye un ensayo de fase 1b dedicado a mCRPC en pacientes sin tratamiento previo y con experiencia con PLUVICTO®, y un segundo ensayo de fase 1b en cesta...

04/05/2026 AKTS_US — Yahoo Finance
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
04/05/2026 AKTS_US — Stock Titan
Aktis opens prostate cancer study as it broadens AKY-2519 testing
04/05/2026 AKTS_US — Investing.com
Aktis initiates phase 1b trial of AKY-2519 in prostate cancer
04/05/2026 AKTS_US — ChartMill
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
04/05/2026 AKTS_US — ChartMill
AKTS Technical Analysis | Trend, Signals & Chart Patterns | AKTIS ONCOLOGY INC (NASDAQ:AKTS)
03/05/2026 AKTS_US — The Globe and Mail ES ← EN
Los analistas de Wall Street son optimistas sobre las principales opciones de atención médica

Wall Street Analysts Are Bullish on Top Healthcare Picks

03/05/2026 AKTS_US — Stock Titan
UCB strikes up to $2.2B Candid deal, spotlighting Two River and Vida
01/05/2026 AKTS_US — Intellectia AI
SPTX Financials: Revenue Breakdown, Margins & Competitor Comparison
30/04/2026 AKTS_US — Sahm
This Hyperfine Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday
29/04/2026 AKTS_US — Moomoo
William Blair Initiates Aktis Oncology at Outperform
29/04/2026 AKTS_US — Benzinga
This Hyperfine Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday
29/04/2026 AKTS_US — Moomoo
William Blair Initiates Aktis Oncology at Outperform
28/04/2026 AKTS_US — The Business Journals
Massachusetts biotech IPOs surge after years of drought
28/04/2026 AKTS_US — Seeking Alpha
Aktis Oncology: 'Buy' Based On Radiotherapeutic Isotope Design For Broad Targeting (AKTS)

Las acciones de Aktis Oncology (AKTS) reciben una calificación de "Compra", impulsada por sus innovadores radioconjugados de miniproteínas dirigidos a tumores sólidos Nectin-4 y B7-H3. Lea el análisis completo aquí.

Página 2 de 7

keyboard_arrow_up